Sort by

Send to

Choose Destination

Search results

Items: 14


Cervical Cancer Prevention and Cancer Control in Latin America-Letter.

Vidaurre T.

Clin Cancer Res. 2015 Dec 15;21(24):5644-5. doi: 10.1158/1078-0432.CCR-15-1238. No abstract available.


PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.

Castaneda CA, Lopez-Ilasaca M, Pinto JA, Chirinos-Arias M, Doimi F, Neciosup SP, Rojas KI, Vidaurre T, Balko JM, Arteaga CL, Gomez HL.

Hematol Oncol Stem Cell Ther. 2014 Dec;7(4):142-8. doi: 10.1016/j.hemonc.2014.09.007. Epub 2014 Oct 29.


Cost-effectiveness analysis of breast cancer control interventions in Peru.

Zelle SG, Vidaurre T, Abugattas JE, Manrique JE, Sarria G, Jeronimo J, Seinfeld JN, Lauer JA, Sepulveda CR, Venegas D, Baltussen R.

PLoS One. 2013 Dec 10;8(12):e82575. doi: 10.1371/journal.pone.0082575. eCollection 2013.


Trends in head and neck cancers in Peru between 1987 and 2008: Experience from a large public cancer hospital in Lima.

Walter L, Vidaurre T, Gilman RH, Poquioma E, Olaechea C, Gravitt PE, Marks MA.

Head Neck. 2014 May;36(5):729-34. doi: 10.1002/hed.23369. Epub 2013 Sep 2.


[The role of the National Institute of Neoplastic Diseases in the control of cancer in Peru].

Salazar MR, Regalado-Rafael R, Navarro JM, Montanez DM, Abugattas JE, Vidaurre T.

Rev Peru Med Exp Salud Publica. 2013 Mar;30(1):105-12. Spanish.


Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers.

Santarpia L, Qi Y, Stemke-Hale K, Wang B, Young EJ, Booser DJ, Holmes FA, O'Shaughnessy J, Hellerstedt B, Pippen J, Vidaurre T, Gomez H, Valero V, Hortobagyi GN, Symmans WF, Bottai G, Di Leo A, Gonzalez-Angulo AM, Pusztai L.

Breast Cancer Res Treat. 2012 Jul;134(1):333-43. doi: 10.1007/s10549-012-2035-3. Epub 2012 Apr 27.


A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.

Carlson RW, O'Neill A, Vidaurre T, Gomez HL, Badve SS, Sledge GW.

Breast Cancer Res Treat. 2012 Jun;133(3):1049-56. doi: 10.1007/s10549-012-1997-5. Epub 2012 Mar 15.


A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.

Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF.

JAMA. 2011 May 11;305(18):1873-81. doi: 10.1001/jama.2011.593.


Prognostic effect of hormone receptor status in early HER2 positive breast cancer patients.

Gómez HL, Castañeda CA, Vigil CE, Vidaurre T, Velarde RG, Cruz WR, Pinto JA, Suazo JF, Garcés MR, Neciosup SP, Vallejos CS.

Hematol Oncol Stem Cell Ther. 2010;3(3):109-15.


Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer.

Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, Qi Y, Barajas-Figueroa LJ, Souchon E, Coutant C, Doimi FD, Ibrahim NK, Gong Y, Hortobagyi GN, Hess KR, Symmans WF, Pusztai L.

Clin Cancer Res. 2010 Nov 1;16(21):5351-61. doi: 10.1158/1078-0432.CCR-10-1265. Epub 2010 Sep 9.


Topoisomerase II-α as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer.

Gómez HL, Pinto JA, Olivera M, Vidaurre T, Doimi FD, Vigil CE, Velarde RG, Abugattas JE, Alarcón E, Vallejos CS.

Breast. 2011 Feb;20(1):39-45. doi: 10.1016/j.breast.2010.06.009. Epub 2010 Aug 12.


Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development.

Vidaurre T, Wilkerson J, Simon R, Bates SE, Fojo T.

Cancer J. 2009 Sep-Oct;15(5):366-73. doi: 10.1097/PPO.0b013e3181b9d37b. Review.


Breast cancer in Latin America: results of the Latin American and Caribbean Society of Medical Oncology/Breast Cancer Research Foundation expert survey.

Cazap E, Buzaid AC, Garbino C, de la Garza J, Orlandi FJ, Schwartsmann G, Vallejos C, Guercovich A; Latin American and Caribbean Society of Medical Oncology.

Cancer. 2008 Oct 15;113(8 Suppl):2359-65. doi: 10.1002/cncr.23834.


Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.

Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gómez HL, Hortobagyi GN, Pusztai L.

J Clin Oncol. 2006 Sep 10;24(26):4236-44. Epub 2006 Aug 8.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk